Risk of injury associated with skeletal muscle relaxant use in older adults;Risque de Blessure Associée à l'Utilisation de Myorelaxants chez les Personnes Agées

Annals of Pharmacotherapy

Volumn 47, Issue 7-8, 2013, Pages 993-998

  Spence, Michele M ^a   Shin, Patrick J ^b   Lee, Eric A ^c   Gibbs, Nancy E ^d  

^a Pharmacy Outcomes Research Group   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c West Los Angeles Medical Center   (United States)

^d KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARISOPRODOL; CHLORZOXAZONE; CYCLOBENZAPRINE; METAXALONE; METHOCARBAMOL; MUSCLE RELAXANT AGENT; ORPHENADRINE;

AGED; ARTICLE; CASE CONTROL STUDY; CONCUSSION; CONTROLLED STUDY; CONTUSION; CRUSH TRAUMA; DISLOCATION; DRUG USE; ELDERLY CARE; EMERGENCY WARD; FALL RISK; FALLING; FEMALE; FRACTURE; HOSPITALIZATION; HUMAN; INJURY; INTEGRATED HEALTH CARE SYSTEM; LACERATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SKELETAL MUSCLE;

AGE FACTORS; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; EMERGENCY MEDICAL SERVICES; FEMALE; HOSPITALIZATION; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; RISK FACTORS; WOUNDS AND INJURIES;

EID: 84880075003     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R735     Document Type: Article

References (23)

1. Product information. Soma (carisoprodol) tablet. Somerset, NJ: Meda Pharmaceuticals, Inc., October 2009.
2. Product information. Lorzone (chlorzoxazone) tablet. Sayreville, NJ: Vertical Pharmaceuticals, Inc., September 2010.
3. Product information. Flexeril (cyclobenzaprine hydrochloride) tablet, film coated. Titusville, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., January 2010.
4. Product information. Skelaxin (metaxalone). Bristol, TN: King Pharmaceuticals, Inc., April 2008.
5. Product information. Robaxin (methocarbamol) tablet, film coated. Smyrna, GA: Schwarz Pharma LLC, September 2009.
6. Product information. Norflex (orphenadrine citrate) tablet, extended-release. Northridge, CA: 3M Pharmaceuticals, October 2006.
7. Drug Facts & Comparisons (online). Wolters Kluwer. 1974-2012. www. drugs.com/ppa (accessed 2013 Mar 1).
8. See S, Ginzburg R. Choosing a skeletal muscle relaxant. Amer Fam Phys 2008;78:365-70. http://www.aafp.org/afp/2008/0801/p365.html (accessed 2013 Mar 1).
9. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev 2003;(2):CD004252. doi: 10.1002/14651858.CD004252
10. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-doi: 10.1111/j.1532-5415.2012.03923.x
11. Shrank WH, Polinski JM, Avorn J. Quality indicators for medication use in vulnerable elders. J Am Geriatr Soc 2007;55:S373-81. doi: 10.1111/j.1532-5415.2007.01345.x
12. HEDIS drugs to avoid in the elderly (DAE). www.ncqa.org/Portals/0/ Newsroom/SOHC/Drugs_Avoided_Elderly.pdf (accessed 2013 Mar 1).
13. HEDIS potentially harmful drug-disease interactions in the elderly (DDE-G). www.ncqa.org/tabid/598/default.aspx (accessed 2013 Mar 12).
14. Dillon C, Paulose-Ram R, Hirsch R, Gu Q. Skeletal muscle relaxant use in the United States: data from the Third National Health and Nutrition Examination Survey (NHANES III). Spine 2004;29:892-6. doi: 10.1097/00007632-200404150-00014
15. Coutinho ES, Fletcher A, Bloch KV, Rodriques LC. Risk factors for falls with severe fracture in elderly people living in a middle-income country: a case control study. BMC Geriatr 2008;8:21. doi: 10.1186/147102318-8-21
16. Golden AG, Ma Q, Nair V, Florez HJ, Roos BA. Risk for fractures with centrally acting muscle relaxants: an analysis of a national Medicare advantage claims database. Ann Pharmacother 2010;44:1369-75. doi: 10.1345/aph.1P210
17. Billups SJ, Delate T, Hoover B. Injury in an elderly population before and after initiating a skeletal muscle relaxant. Ann Pharmacother 2011; 45:485-91. doi: 10.1345/aph.1P628
18. Tamblyn R, Reid T, Mayo N, et al. Using medical services claims to assess injuries in the elderly: sensitivity of diagnostic and procedure codes for injury ascertainment. J Clin Epidemiol 2000;53:183-94. doi: 10.1016/S0895-4356(99)00136-5
19. Tamblyn R, Abrahamawicz M, du Berger R, et al. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005;53:233-41. doi: 10.1111/j.1532-5415.2005.53108.x
20. Rothman KJ, Greenland S. Case-control studies. In: Rothman KJ, Greenland S, eds. Modern epidemiology, 2nd ed. Philadelphia: Lippincott-Raven Publishers, 1998:93-114.
21. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin. Arch Intern Med 2006;166:241-6. doi: 10.1001/archinte.166.2.241
22. Ash AS, Ellis RP, Pope GC, et al. Using diagnoses to describe populations and predict costs. Health Care Financ Rev 2000;21:7-28. www.cms.gov/ HealthCareFinancingReview/Downloads/00springpg7.pdf (accessed 2013 Apr 2).
23. American Geriatrics Society. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009;57:1331-46. doi: 10.1111/j.1532-5415.2009.02376.x